Citations

Clear

119 citation(s) found for "Sheehan, J".

Recurrence after cure in cranial dural arteriovenous fistulas: a collaborative effort by the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR)
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R., Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Bulters, Diederik, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Amin-Hanjani, Sepideh, Alaraj, Ali, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Abla, Adib, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Abecassis, Isaac Josh, Meyer, R. Michael, Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 981-989

10.3171/2021.1.jns202033 | PMID 34507283 Get It

OBJECTIVE Cranial dural arteriovenous fistulas (dAVFs) are often treated with endovascular therapy, but occasionally a multimodality approach including surgery and/or radiosurgery is utilized. Recurrence after an initial angiographic cure has been reported, with estimated rates ranging from 2% to 14.3%, but few risk factors have been identified. The objective of this study was to identify risk factors associated with recurrence of dAVF after putative cure. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) data were retrospectively reviewed. All patients with angiographic cure after treatment and subsequent angiographic follow-up were included. The primary outcome was recurrence, with risk factor analysis. Secondary outcomes included clinical outcomes, morbidity, and mortality associated with recurrence. Risk factor analysis was performed comparing the group of patients who experienced recurrence with those with durable cure (regardless of multiple recurrences). Time-to-event analysis was performed using all collective recurrence events (multiple per patients in some cases). RESULTS Of the 1077 patients included in the primary CONDOR data set, 457 met inclusion criteria. A total of 32 patients (7%) experienced 34 events of recurrence at a mean of 368.7 days (median 192 days). The recurrence rate was 4.5% overall. Kaplan-Meier analysis predicted long-term recurrence rates approaching 11% at 3 years. Grade III dAVFs treated with endovascular therapy were statistically significantly more likely to experience recurrence than those treated surgically (13.3% vs 0%, p = 0.0001). Tentorial location, cortical venous drainage, and deep cerebral venous drainage were all risk factors for recurrence. Endovascular intervention and radiosurgery were associated with recurrence. Six recurrences were symptomatic, including 2 with hemorrhage, 3 with nonhemorrhagic neurological deficit, and 1 with progressive flow-related symptoms (decreased vision). CONCLUSIONS Recurrence of dAVFs after putative cure can occur after endovascular treatment. Risk factors include tentorial location, cortical venous drainage, and deep cerebral drainage. Multimodality therapy can be used to achieve cure after recurrence. A delayed long-term angiographic evaluation (at least 1 year from cure) may be warranted, especially in cases with risk factors for recurrence.
Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations
Mathieu, David, Kotecha, Rupesh, Sahgal, Arjun, Salles, Antonio De, Fariselli, Laura, Pollock, Bruce E., Levivier, Marc, Ma, Lijun, Paddick, Ian, Regis, Jean, Yomo, Shoji, Suh, John H., Rubens, Muni, Sheehan, Jason P., Mathieu, David , Rubens, Muni , Yomo, Shoji , Mathieu, David , Kotecha, Rupesh, Sahgal, Arjun, Salles, Antonio De, Fariselli, Laura, Pollock, Bruce E., Levivier, Marc, Ma, Lijun, Paddick, Ian, Regis, Jean, Suh, John H., Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery | September 3, 2021 | Volume: 136 | Issue: 3 | Pages: 801-812

10.3171/2021.2.jns204440 | PMID 34479203 Get It

OBJECTIVE A systematic review was performed to provide objective evidence on the use of stereotactic radiosurgery (SRS) in the management of secretory pituitary adenomas and develop consensus recommendations. METHODS The authors performed a systematic review of the English-language literature up until June 2018 using the PRISMA guidelines. The PubMed (Medline), Embase, and Cochrane databases were searched. A total of 45 articles reporting single-institution outcomes of SRS for acromegaly, Cushing’s disease, and prolactinomas were selected and included in the analysis. RESULTS For acromegaly, random effects meta-analysis estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rates were 97.0% (95% CI 96.0%–98.0%), 44.0% (95% CI 35.0%–53.0%), and 17.0% (95% CI 13.0%–23.0%), respectively. For Cushing’s disease, random effects estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 92.0% (95% CI 87.0%–95.0%), 48.0% (95% CI 35.0%–61.0%), and 21.0% (95% CI 13.0%–31.0%), respectively. For prolactinomas, random effects estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 93.0% (95% CI 90.0%–95.0%), 28.0% (95% CI 19.0%–39.0%), and 12.0% (95% CI 6.0%–24.0%), respectively. Meta-regression analysis did not show a statistically significant association between mean margin dose with crude endocrine remission rate or mean margin dose with development of any new hypopituitarism rate for any of the secretory subtypes. CONCLUSIONS SRS offers effective tumor control of hormone-producing pituitary adenomas in the majority of patients but a lower rate of endocrine improvement or remission.
Outcome Following Hemorrhage From Cranial Dural Arteriovenous Fistulae
Koch, Matthew J. , Stapleton, Christopher J. , Guniganti, Ridhima , Lanzino, Giuseppe , Sheehan, Jason P. , Alaraj, Ali , Bulters, Diederik , Kim, Louis J. , Fox, W. Christopher , Gross, Bradley A. , Hayakawa, M. , Dijk, J. Marc C. van , Starke, Robert M., Satomi, Junichiro, Polifka, Adam , Zipfel, Gregory J. , Amin‐Hanjani, Sepideh , Derdeyn, Colin P. , Sheehan, Jason , Kim, Louis J. , van DijK, J Marc C , Amin-Hanjani, Sepideh , Alaraj, Ali , Fox, W Christopher , Lanzino, Giuseppe , Bulters, Diederik O , Derdeyn, Colin P , Gross, Bradley

Mayo Clinic

Stroke | August 26, 2021 | Volume: 52 | Issue: 10 | Pages: No page available

10.1161/strokeaha.121.034707 | PMID 34433307 Get It

Background and Purpose: Dural arteriovenous fistulae can present with hemorrhage, but there remains a paucity of data regarding subsequent outcomes. We sought to use the CONDOR (Consortium for Dural Arteriovenous Fistula Outcomes Research), a multi-institutional registry, to characterize the morbidity and mortality of dural arteriovenous fistula–related hemorrhage. Methods: A retrospective review of patients in CONDOR who presented with dural arteriovenous fistula–related hemorrhage was performed. Patient characteristics, clinical follow-up, and radiographic details were analyzed for associations with poor outcome (defined as modified Rankin Scale score ≥3). Results: The CONDOR dataset yielded 262 patients with incident hemorrhage, with median follow-up of 1.4 years. Poor outcome was observed in 17.0% (95% CI, 12.3%–21.7%) at follow-up, including a 3.6% (95% CI, 1.3%–6.0%) mortality. Age and anticoagulant use were associated with poor outcome on multivariable analysis (odds ratio, 1.04, odds ratio, 5.1 respectively). Subtype of hemorrhage and venous shunting pattern of the lesion did not affect outcome significantly. Conclusions: Within the CONDOR registry, dural arteriovenous fistula–related hemorrhage was associated with a relatively lower morbidity and mortality than published outcomes from other arterialized cerebrovascular lesions but still at clinically consequential rates.
Benzodiazepine administration patterns before escalation to second‐line medications in pediatric refractory convulsive status epilepticus
Sheehan, Theodore , Amengual‐Gual, Marta , Vasquez, Alejandra , Abend, Nicholas S. , Anderson, Anne E. , Arya, Ravindra , Aguilar, Cristina Barcia , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Gaínza‐Lein, Marina , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Jackson, Michele , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Reece, Latania, Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Shellhaas, Renée A. , Smith, Garnett , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Arya, Ravindra , Barcia Aguilar, Cristina , Farias-Moeller, Raquel , Gaillard, William D , Gaínza-Lein, Marina , Guerriero, Rejean M , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Shellhaas, Renée A , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Sheehan, Theodore , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 11 | Pages: 2766-2777

10.1111/epi.17043 | PMID 34418087 Get It

Abstract Objective This study was undertaken to evaluate benzodiazepine (BZD) administration patterns before transitioning to non‐BZD antiseizure medication (ASM) in pediatric patients with refractory convulsive status epilepticus (rSE). Methods This retrospective multicenter study in the United States and Canada used prospectively collected observational data from children admitted with rSE between 2011 and 2020. Outcome variables were the number of BZDs given before the first non‐BZD ASM, and the number of BZDs administered after 30 and 45 min from seizure onset and before escalating to non‐BZD ASM. Results We included 293 patients with a median (interquartile range) age of 3.8 (1.3–9.3) years. Thirty‐six percent received more than two BZDs before escalating, and the later the treatment initiation was after seizure onset, the less likely patients were to receive multiple BZD doses before transitioning (incidence rate ratio [IRR] = .998, 95% confidence interval [CI] = .997–.999 per minute, p = .01). Patients received BZDs beyond 30 and 45 min in 57.3% and 44.0% of cases, respectively. Patients with out‐of‐hospital seizure onset were more likely to receive more doses of BZDs beyond 30 min (IRR = 2.43, 95% CI = 1.73–3.46, p < .0001) and beyond 45 min (IRR = 3.75, 95% CI = 2.40–6.03, p < .0001) compared to patients with in‐hospital seizure onset. Intermittent SE was a risk factor for more BZDs administered beyond 45 min compared to continuous SE (IRR = 1.44, 95% CI = 1.01–2.06, p = .04). Forty‐seven percent of patients ( n = 94) with out‐of‐hospital onset did not receive treatment before hospital arrival. Among patients with out‐of‐hospital onset who received at least two BZDs before hospital arrival ( n = 54), 48.1% received additional BZDs at hospital arrival. Significance Failure to escalate from BZDs to non‐BZD ASMs occurs mainly in out‐of‐hospital rSE onset. Delays in the implementation of medical guidelines may be reduced by initiating treatment before hospital arrival and facilitating a transition to non‐BZD ASMs after two BZD doses during handoffs between prehospital and in‐hospital settings.
Factors associated with long‐term outcomes in pediatric refractory status epilepticus
Gaínza‐Lein, Marina , Aguilar, Cristina Barcia , Piantino, Juan , Chapman, Kevin , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Nayak, Anuranjita , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Reece, Latania, Riviello, James J. , Sannagowdara, Kumar , Sands, Tristan T. , Sheehan, Theodore , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Arya, Ravindra , Farias-Moeller, Raquel , Gaillard, William D , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Sheehan, Theodore , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | July 12, 2021 | Volume: 62 | Issue: 9 | Pages: 2190-2204

10.1111/epi.16984 | PMID 34251039 Get It

AbstractObjectiveThis study was undertaken to describe long‐term clinical and developmental outcomes in pediatric refractory status epilepticus (RSE) and identify factors associated with new neurological deficits after RSE.MethodsWe performed retrospective analyses of prospectively collected observational data from June 2011 to March 2020 on pediatric patients with RSE. We analyzed clinical outcomes from at least 30 days after RSE and, in a subanalysis, we assessed developmental outcomes and evaluated risk factors in previously normally developed patients.ResultsFollow‐up data on outcomes were available in 276 patients (56.5% males). The median (interquartile range [IQR]) follow‐up duration was 1.6 (.9–2.7) years. The in‐hospital mortality rate was 4% (16/403 patients), and 15 (5.4%) patients had died after hospital discharge. One hundred sixty‐six (62.9%) patients had subsequent unprovoked seizures, and 44 (16.9%) patients had a repeated RSE episode. Among 116 patients with normal development before RSE, 42 of 107 (39.3%) patients with available data had new neurological deficits (cognitive, behavioral, or motor). Patients with new deficits had longer median (IQR) electroclinical RSE duration than patients without new deficits (10.3 [2.1–134.5] h vs. 4 [1.6–16] h, p = .011, adjusted odds ratio = 1.003, 95% confidence interval = 1.0008–1.0069, p = .027). The proportion of patients with an unfavorable functional outcome (Glasgow Outcome Scale‐Extended score ≥ 4) was 22 of 90 (24.4%), and they were more likely to have received a continuous infusion.SignificanceAbout one third of patients without prior epilepsy developed recurrent unprovoked seizures after the RSE episode. In previously normally developing patients, 39% presented with new deficits during follow‐up, with longer electroclinical RSE duration as a predictor.
Abstract 125: Observation versus Treatment for Low-Grade Intracranial Dural Arteriovenous Fistulas: A Multicenter Matched Cohort Study
Chen, Ching‐Jen, Buell, Thomas J. , Guniganti, Ridhima , Abecassis, Isaac Josh, Kansagra, Akash P. , Starke, Robert M., Gross, Bradley A. , Durnford, Andrew , Kim, Louis J. , Dijk, Marc Van , Zipfel, Gregory J. , Sheehan, Jason P. , CONDOR, Lanzino, Giuseppe , Derdeyn, Colin P. , Amin-Hanjani, Sepideh , Levitt, Michael R. , Alaraj, Ali , Fox, W Christopher , Gross, Bradley , Bulters, Diederik , Kim, Louis J. , Dijk, Marc van, CONDOR

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.125 Get It

Background and Purpose: Given the benign natural history of intracranial low-grade dural arteriovenous fistulas (dAVFs), their routine treatment remains controversial. The aim of this study is to compare the outcomes of low-grade dAVF treatment to conservative management. Methods: We performed a retrospective review of dAVF patients derived from 12 institutions participating in the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR). Patients with low-grade (Borden I) dAVFs were included and categorized into treatment and observation cohorts. Primary outcome was defined as modified Rankin Scale (mRS) score at final follow-up. Secondary outcomes were rates of excellent (mRS 0-1) and good (mRS 0-2) functional outcomes, symptomatic improvement, mortality, and obliteration at final follow-up. Results: The treatment and observation cohorts comprised 230 and 112 patients, respectively. At last follow up, no difference in primary or secondary outcomes was observed between the two cohorts, with the exception of obliteration, which was higher in the treatment cohort (79.3% vs. 28.2%, p<0.001; Table 1). The two cohorts were then matched in a 1:1 ratio, resulting in 64 patients in each matched cohort. No difference in primary or secondary outcomes was observed between the matched cohorts, with the exception of obliteration, which was higher in the matched treatment cohort (75.4% vs. 28.6%, p<0.001; Table 2). Subgroup analysis of symptomatic patients demonstrated higher obliteration rate in the treatment cohort, but no difference in primary or other secondary outcomes were found. Conclusions: Low-grade dAVF treatment was not associated with increased functional disability compared to conservative management. Although higher obliteration rates were achieved in the treatment cohort, rates of symptomatic improvement were similar between the two cohorts. This study did not provide evidence to support the routine treatment of low-grade dAVFs.
Contribution of intramuscular TG and plasma FFA to the long chain acyl‐carnitine pool: effects of insulin in trained and untrained humans
Sheehan, Michael T. , Guo, ZengKui, Jensen, Michael D. , Kanaley, Jill A.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.958.1 Get It

This study examined the plasma FFA, intramuscular long chain acylcarnitine (LCAC) fatty acids and imTG stores during basal and hyperinsulinemic conditions. Methods: Endurance trained (TR, n=8) and sedentary individuals (SED, n=15) were studied under overnight postabsorptive and euglycemic hyperinsulinemic clamp (1.0mU·kg FFM −1 ·min −1 ) conditions. FFA kinetics were measured using a 5‐h infusion of [U‐ 13 C]oleate, for labeling of imTG and LCAC pools. Muscle biopsies were performed to measure imTG and imLCAC enrichment at 1400 h after 5‐h of infusion. imTG concentrations were greater in TR than SED individuals (P<0.01). Table SED Trained Saline** Clamp Saline** Clamp plasma oleate FFA (mpe) 0.210±0.018* 0.271±0.036* 0.189±0.026* 0.361±0.050* imLCAC (mpe) 0.025±0.003 0.005±0.002 0.016±0.005 0.002±0.002 imTG (mpe) 0.018±0.003† 0.011±0.001† 0.024±0.004† 0.013±0.001† P<0.001 saline vs. clamp; *P<0.000 between compartment (plasma vs. imLCAC vs. imTG); †P<0.000 imLCAC and imTG Methods: Endurance trained (TR, n=8) and sedentary individuals (SED, n=15) were studied under overnight postabsorptive and euglycemic hyperinsulinemic clamp (1.0mU·kg FFM −1 ·min −1 ) conditions. FFA kinetics were measured using a 5‐h infusion of [U‐ 13 C]oleate, for labeling of imTG and LCAC pools. Muscle biopsies were performed to measure imTG and imLCAC enrichment at 1400 h after 5‐h of infusion. Conclusion: The imTG contributes more to the imLCAC pools than plasma FFA both in the basal and hyperinsulinemic state, and hyperinsulinemia suppressed oleate FFA entry into the imLCAC pools, more so in trained than untrained adults. Muscle fatty acid oxidation is largely via obligatory cycling of fatty acids through imTG or other intracellular complex lipid pools.
CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity
Ernst, Michelle, Baugh, Evan H., Thomas‐Wilson, Amanda , Bier, Louise , Lippa, Natalie , Stong, Nicholas , Mulhern, Maureen , Kushary, Sulagna , Akman, Cigdem I. , Heinzen, Erin L. , Yeh, Raymond, He, Weimin , Hanchard, Neil A. , Burrage, Lindsay C. , Leduc, Magalie S. , Chong, Josephine S. C., Bend, Renee, Lyons, Michael J. , Lee, Jennifer A. , Suwannarat, Pim, Brilstra, Eva H. , Simon, Marleen, Binsbergen, Ellen van , Groepper, Daniel , Fleischer, Julie , Keren, Boris , Mignot, Cyril , Mathieu, Sophie , Mancini, Grazia M.S. , Madan‐Khetarpal, Suneeta, Infante, Elena , Bluvstein, Judith , Seeley, Andrea , Bachman, Kristine , Klee, Eric W. , Schultz‐Rogers, Laura , Hasadsri, Linda , Barnett, Sarah , Ellingson, Marissa S. , Ferber, Matthew J. , Ramsey, Keri , Rauch, Anita , Joset, Pascal , Steindl, Katharina , Sheehan, Theodore , Vasquez, Alejandra , Ruivenkamp, Claudia , White, Susan M. , Monaghan, Kristin G. , Goldstein, David B. , Sands, Tristan T. , Aggarwal, Vimla S. , Ernst, Michelle E , Schultz-Rogers, Laura E, Sheehan, Theodore , Poduri, Annapurna , Sands, Tristan T , Rauch, Anita , Burrage, Lindsay C , Stong, Nicholas , Yeh, Raymond, Koopmans, Marion , Nava, Caroline , Narayanan, Vinodh , Pais, Lynn

Mayo Clinic

Epilepsia | May 27, 2021 | Volume: 62 | Issue: 7 | Pages: No page available

10.1111/epi.16931 | PMID 34041744 Get It

AbstractCSNK2B has recently been implicated as a disease gene for neurodevelopmental disability (NDD) and epilepsy. Information about developmental outcomes has been limited by the young age and short follow‐up for many of the previously reported cases, and further delineation of the spectrum of associated phenotypes is needed. We present 25 new patients with variants in CSNK2B and refine the associated NDD and epilepsy phenotypes. CSNK2B variants were identified by research or clinical exome sequencing, and investigators from different centers were connected via GeneMatcher. Most individuals had developmental delay and generalized epilepsy with onset in the first 2 years. However, we found a broad spectrum of phenotypic severity, ranging from early normal development with pharmacoresponsive seizures to profound intellectual disability with intractable epilepsy and recurrent refractory status epilepticus. These findings suggest that CSNK2B should be considered in the diagnostic evaluation of patients with a broad range of NDD with treatable or intractable seizures.
Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study
Fribance, Sarah , Pikis, Stylianos , Lee, John Y. K. , Buch, Love, Bernstein, Kenneth , Mathieu, David , Perron, Rémi, Patel, Samir , Álvarez, Roberto Martínez , Moreno, Nuria Martínez , Lee, Cheng‐Chia , Strickland, Ben A. , Zada, Gabriel , Chang, Eric L. , Kondziolka, Douglas , Sheehan, Jason P. , Mathieu, David , Kondziolka, Douglas , Bunevičius, Adomas , Moran, Michael, Yang, Andrew I. , Liščák, Roman , Šimonová, Gabriela , Trifiletti, Daniel M. , Yang, Huai‐Che

Mayo Clinic

Thyroid® | May 12, 2021 | Volume: 31 | Issue: 8 | Pages: 1244-1252

10.1089/thy.2020.0947 | PMID 33978475 Get It

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1–10 BMs). The median SRS treatment volume was 0.79 cm 3 (range: 0.003–38.18 cm 3 ), and the median SRS prescription dose was 20 Gy (range: 8–24 Gy). The median survival after SRS for BMs was 14 months (range: 3–58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143–11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689–0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
A Case of Sheehan Syndrome 7 Years Postpartum with Transaminitis and Hyperlipidemia
Sadiq, Sanah, Chowdhury, Arnab

Mayo Clinic

American Journal of Case Reports | April 15, 2021 | Volume: 22 | Issue: No issue available | Pages: No page available

10.12659/ajcr.930908 | PMID 33951030 Get It